Follow
Ignace Vergote
Ignace Vergote
Professor of Gynecologic Oncology, University of Leuven
Verified email at uzleuven.be
Title
Cited by
Cited by
Year
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ...
New England Journal of Medicine 363 (10), 943-953, 2010
27012010
Endometrial cancer
F Amant, P Moerman, P Neven, D Timmerman, E Van Limbergen, ...
The Lancet 366 (9484), 491-505, 2005
23632005
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
23542016
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
20542012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
16902014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ...
Obstetrical & Gynecological Survey 69 (7), 402-404, 2014
16422014
Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ...
New England Journal of Medicine 381 (25), 2391-2402, 2019
16352019
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
16142017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
15392017
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ...
New England Journal of Medicine 381 (25), 2416-2428, 2019
14462019
Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
MJ Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, ...
Journal of the National Cancer Institute 92 (9), 699-708, 2000
12982000
Epithelial ovarian cancer
S Lheureux, C Gourley, I Vergote, AM Oza
The Lancet 393 (10177), 1240-1253, 2019
12712019
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ...
International Journal of Gynecologic Cancer 31 (1), 2021
12242021
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and …
J Bonneterre, B Thürlimann, JFR Robertson, M Krzakowski, L Mauriac, ...
Journal of Clinical Oncology 18 (22), 3748-3757, 2000
11222000
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group
D Timmerman, L Valentin, TH Bourne, WP Collins, H Verrelst, I Vergote
Ultrasound in Obstetrics and Gynecology: The Official Journal of the …, 2000
10572000
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ...
Annals of Oncology 30 (5), 672-705, 2019
9872019
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
AG Van der Zee, MH Oonk, JA De Hullu, AC Ansink, I Vergote, ...
8982008
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, JFR Robertson, J Quaresma Albano, A Aschermannova, ...
Journal of Clinical Oncology 20 (16), 3396-3403, 2002
8652002
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the …
J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ...
Journal of Clinical Oncology 24 (29), 4699-4707, 2006
8462006
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
I Vergote, J De Brabanter, A Fyles, K Bertelsen, N Einhorn, P Sevelda, ...
The lancet 357 (9251), 176-182, 2001
7872001
The system can't perform the operation now. Try again later.
Articles 1–20